Remarkable Technologies, Inc. enters exclusive license agreement with NeuroEM Therapeutics, Inc. on head-wearable device to treat Alzheimer’s Disease

Connecticut-based Remarkable Technologies, Inc. announced today that it has entered into an exclusive patent license agreement with Arizona-based NeuroEM Therapeutics, Inc.  NeuroEM will have exclusive rights to the head-wearable device developed by Remarkable Technologies as an application of NeuroEM’s electromagnetic research and technology against Alzheimer’s Disease.  Remarkable Technologies received a patent (U.S. 9,037,268) last year regarding the design of a head-wearable device that emits electromagnetic waves.  NeuroEM also developed a related device which will be utilized in an upcoming Phase I clinical trial in Alzheimer’s patients.  The licensed head-wearable device from Remarkable Technologies complements NeuroEM Therapeutics’ patented and patent-pending technologies to use electromagnetic treatment against Alzheimer’s Disease.

Eric Knight, founder and president of Remarkable Technologies, said, “This is a bold step in the battle against this truly horrific disease.  The opportunity to work with the world-leading company in this field — NeuroEM Therapeutics — gives us, in my opinion, the very best chance at tackling Alzheimer’s.”  Knight continued, “At the helm of NeuroEM Therapeutics is Dr. Gary Arendash, the renowned authority in applying radio-wave technologies for neurological therapies.  Dr. Arendash’s lofty industry presence includes his role as the Senior Editor of the Journal of Alzheimer’s Disease.  I simply could not imagine entering into an exclusive license agreement with a finer company — one which has pioneered the use of electromagnetic technology against Alzheimer’s Disease.  NeuroEM’s extensive pre-clinical work in animal models for the disease suggests that their technology could stop or even reverse Alzheimer’s memory impairment.”

Dr. Arendash, CEO and president of NeuroEM Therapeutics, Inc., said, “It is a pleasure to work with Eric Knight, one of the leading inventors in America.  We are pleased that an exclusive license agreement has been established with Eric Knight and his company, Remarkable Technologies, given Eric Knight’s passion to be involved in the development of electromagnetic waves as an effective therapeutic against Alzheimer’s Disease.  We are reviewing how certain aspects of the head-wearable device developed by Remarkable Technologies may be incorporated into clinical devices that NeuroEM will utilize in future clinical trials.”  NeuroEM’s initial clinical trial will be done at the Banner Sun Health Research Institute and Banner Alzheimer’s Institute, both in Phoenix.  The trial, which will utilize the head device developed by NeuroEM, is anticipated to start this Fall and be completed by early next Spring.

About Remarkable Technologies, Inc.
Remarkable Technologies, Inc., located in Farmington, Connecticut, was founded in 1994 by inventor and entrepreneur, Eric Knight.  His vision was to create a company that provides innovative products and services that enhance business and empower people — and those remain the company’s guiding principles today.  The company is actively involved in a diverse array of projects and programs that include novel computer technologies, athletic training systems, aerospace initiatives, advanced RF-based systems, environmental “green” innovations, Internet-based business services, educational outreach programs, inventor-assistance programs, consumer-product innovations, and public service initiatives.  Since its inception, the company has made conscious efforts to be a good corporate citizen in its local and regional communities. This community-support philosophy is an important cornerstone of the company.  www.RemarkableTechnologies.com

About NeuroEM Therapeutics, Inc.
NeuroEM Therapeutics is a medical device company focused on development of Transcranial Electromagnetic Treatment (TEMT) to treat neurodegenerative disorders such as Alzheimer’s Disease, Traumatic Brain Injury, and Down’s Syndrome.  The company is headquartered in Phoenix, AZ, which is a hub of both pre-clinical and clinical investigation into neurodegenerative disorders and diseases.  As such, NeuroEM Therapeutics is collaborating with leading institutions in the Phoenix area such as Banner Sun Health Research Institute, Banner Alzheimer’s Institute, and Arizona State University.  For more information about NeuroEM Therapeutics, go to www.neuroem.com.